Mitchell Whitehead, MD
Family Medicine · Pensacola, FLNPI 1427460526
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $71,165 of the $82,924 with a category attached, or 85.8%. Kedplasma LLC accounts for 83.2% of it on its own, with 42 other manufacturers making up the rest. 2025 is the largest year on record at $42,911, more than ten times the $4,190 reported in 2019. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 624 payments — averaging $132.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kedplasma LLC$69K
- Gilead$4K
- Viiv Healthcare Company$3K
- AbbVie$1K
- GSK$659
- Theratechnologies Inc.$470
- plus $4K from 37 others
Across 435 payments — averaging $2779.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$744K
- Viiv Healthcare Company$371K
- GSK$94K
What the payments were for
- Consulting fees$71,16586%
- Food & beverage$11,57014%
- Education$1890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$82,924 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 489 | $1,898,169 |
| DovatoDolutegravir Sodium/Lamivudine | 186 | $596,117 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 77 | $355,576 |
| DescovyEmtricitabine/Tenofov Alafenam | 149 | $323,930 |
| TivicayDolutegravir Sodium | 142 | $318,139 |
| SerostimSomatropin | 14 | $286,492 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 71 | $263,306 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 71 | $243,181 |
| JulucaDolutegravir/Rilpivirine | 60 | $204,044 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 50 | $194,142 |
| PrezcobixDarunavir/Cobicistat | 58 | $140,373 |
| OzempicSemaglutide | 93 | $109,148 |
| IsentressRaltegravir Potassium | 54 | $106,780 |
| CabenuvaCabotegravir/Rilpivirine | 14 | $92,615 |
| PifeltroDoravirine | 52 | $86,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $4,464 | $2,416,241688 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Juluca, Cabenuva | $3,219 | $1,474,221473 claims |
| Janssen Products, LPSymtuza | $189 | $355,57677 claims |
| MerckIsentress, Pifeltro, Januvia, Janumet Xr | $461 | $214,898139 claims |
| Johnson & JohnsonPrezcobix | $404 | $140,37358 claims |
| Novo NordiskOzempic | $424 | $109,14893 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $659 | $81,956126 claims |
| Lilly USA, LLCMounjaro | $228 | $60,44058 claims |
| PfizerEliquis | $369 | $58,46162 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall | $323 | $25,13032 claims |
| Boehringer IngelheimJardiance | $83 | $21,87927 claims |
| Janssen Scientific Affairs, LLCEdurant | $19 | $15,61212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Pensacola
- Samuel GreenleePensacola$235K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.